Rubius Therapeutics Inc (NASDAQ:RUBY)

0.23
Delayed Data
As of Feb 08
 -0.033 / -12.55%
Today’s Change
0.14
Today|||52-Week Range
6.54
+31.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$26.6M

Company Description

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Foxboro, MA.

Contact Information

Rubius Therapeutics, Inc.
399 Binney Street
Cambridge Massachusetts 02139
P:(617) 679-9600
Investor Relations:

Employees

Shareholders

Individual stakeholders50.32%
Mutual fund holders16.68%
Other institutional15.56%

Top Executives

Dannielle AppelhansPresident, Chief Executive & Financial Officer
Spencer FiskChief Technical Operations
Mark HernonChief Information Officer
Theo ProukouChief People Officer & Senior Vice President
Greg WhiteheadChief Quality Officer & Senior Vice President